PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS

A compound having the structure of Formula (I):

• wherein:
• A is —CH— or —N—;
• R20 is halogen, —CN, —NO2, —OH, C1-C2alkyl optionally substituted with at least one R28, C2-C6alkenyl optionally substituted with at least one R28;
• C2-C6alkynyl optionally substituted with at least one R31, —N(R21)C(═O)R23, —C(═O)N(R21)(R22), —OR27, —CO2H, —O-alkylene-CO2H, —O-alkylene-C(═O)N(R21)(R22), or —N(R21)C(═O)N(R21)(R22);
• each R21 is independently H, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3-C8cycloalkyl;
• each R22 is independently H, substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3-C8cycloalkyl;
• each R23 is independently substituted or unsubstituted C1-C6alkyl, or substituted or unsubstituted C3-C8cycloalkyl;
• R27 is substituted or unsubstituted C3-C8cycloalkyl or C1-C6alkyl substituted with alkoxy;
• each R24 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SCH3, —N(R21)S(═O)2R23, —S(═O)2N(R21)(R22), —S(═O)R23, —S(═O)2R23, —C(═O)R23, —OC(═O)R23, —CO2R21, —N(R29)(R30), —C(═O)N(R21)(R22), —N(R21)C(═O)R23, —N(R21)C(═O)OR22, —N(R21)C(═O)N(R21)(R22), C1-C2alkyl optionally substituted with at least one R27, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl;
• or substituted or unsubstituted cycloalkyl;
• R28 is halogen, —CN, —NO2, —OH, or substituted or unsubstituted C3-C6cycloalkyl;
• R29 is H, CH3, substituted or unsubstituted cycloalkyl;
• R30 is H, CH3, or substituted or unsubstituted cycloalkyl;
• R31 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR21, —N(R21)S(═O)2R23, —S(═O)2N(R21)(R22), —S(═O)R23, —S(═O)2R23, —C(═O)R23, —OC(═O)R23, —CO2R21, —N(R29)(R30), —C(═O)N(R21)(R22), —N(R21)C(═O)R23, —N(R21)C(═O)OR22, —N(R21)C(═O)N(R21)(R22), substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl;
• or substituted or unsubstituted cycloalkyl;
• n is 0-4;
• or
• when n is 1-4, R20 and R24 together with the carbon atoms to which they are attached form a ring;
• Y is an optionally substituted group selected from among alkylene, heteroalkylene, arylene, heteroarylene, alkylenearylene, alkyleneheteroarylene, alkylenecycloalkylene, alkyleneheterocycloalkylene, cycloalkylene and heterocycloalkylene;
• Z is —C(═O), —N(Ra)C(═O), —N(Ra)S(═O)x, where x is 1 or 2, and Ra is H, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;
• and
• R6 is H or L-J-W;
• R7 and R8 are independently H or L-J-W;
• or R7 and R8 taken together form a bond;
• L and J are each independently a bond, substituted and unsubstituted C1-C6 alkylene, substituted and unsubstituted C3-C6 cycloalkylene, substituted and unsubstituted C1-C6 heteroalkylene, substituted and unsubstituted C2-C7 heterocycloalkylene, substituted and unsubstituted C6-C12 arylene, substituted and unsubstituted C3-C12 heteroarylene, —CO—, —O—, and —S—;
• W is H, or NR25R26;
• R25 and R26 are each independently H, substituted and unsubstituted C1-C6 alkyl, substituted and unsubstituted C3-C6 cycloalkyl, substituted and unsubstituted C1-C6 heteroalkyl, substituted and unsubstituted C2-C7 heterocycloalkyl, substituted and unsubstituted C6-C12 aryl, and substituted and unsubstituted C3-C12 heteroaryl;
• and
• pharmaceutically active metabolites, or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or pharmaceutically acceptable prodrug thereof.